1 minute read | December.28.2022
Orrick advised South San Francisco-based biopharmaceutical company Catalyst Biosciences, Inc. in its acquisition of the F351 program, a next-generation fibrosis drug, from GNI Group Ltd. In a separate transaction, Catalyst agrees to acquire a controlling interest in Beijing Continent, a commercial-stage pharmaceutical company based in China and majority-owned subsidiary of GNI. After both transactions, Catalyst will continue to trade on NASDAQ under the ticker symbol “CBIO”.
The Orrick team advising Catalyst Biosciences was led by Stephen Thau, David Schwartz, and Albert Vanderlaan and includes Jamie Kamen, Hong Tran, Yuan Tian, Gargi Talukder, Alex Straughn, John Narducci, Jamie Larkin, Max Hyatt, Stephen Chao, Jeanine McGuinness and Debbie Abernathy.